Narcolepsy

>

The NeurologyLive® Narcolepsy Disease Spotlight page offers specific updates and coverage on the latest expert conversations and data readouts related to the treatment and management of patients with the sleep disorder.

Latest News

Orexin Receptor Agent ALKS 2680 Meets End Points in Phase 2 VIBRANCE-1 Study
Orexin Receptor Agent ALKS 2680 Meets End Points in Phase 2 VIBRANCE-1 Study

July 21st 2025

New study reveals alixorexton significantly improves wakefulness and reduces daytime sleepiness in narcolepsy type 1, paving the way for phase 3 trials.

Orexin-Targeting Agent TAK-861 Meets All End Points in Phase 3 FirstLight and RadiantLight Studies
Orexin-Targeting Agent TAK-861 Meets All End Points in Phase 3 FirstLight and RadiantLight Studies

July 14th 2025

Yves Dauvilliers, MD  (Credit: CHU de Montpellier)
Phase 2 Published Data of Oveporexton Shows Broad Improvements of Narcolepsy Type 1 Symptoms

July 11th 2025

NeuroVoices: Kumar Budur, MD, MS, on BP1.15205 as a Next-Gen Therapy for Narcolepsy
NeuroVoices: Kumar Budur, MD, MS, on BP1.15205 as a Next-Gen Therapy for Narcolepsy

July 9th 2025

Post Hoc Analyses Shed Light on Safety and Efficacy of Once-Nightly Sodium Oxybate in Narcolepsy Care
Post Hoc Analyses Shed Light on Safety and Efficacy of Once-Nightly Sodium Oxybate in Narcolepsy Care

June 19th 2025

More News

© 2025 MJH Life Sciences

All rights reserved.